Substance / Medication

Amphotericin B

Overview

Active Ingredient
amphotericin B
RxNorm CUI
732

Indications

Amphotericin B liposome for injection is indicated for the following: DOSAGE AND ADMINISTRATION Seefor recommended doses by indication. Empirical therapy for presumed fungal infection in febrile, neutropenic patients. DESCRIPTION OF CLINICAL STUDIES Treatment of Cryptococcal Meningitis in HIV-infected patients (see). Aspergillus Candida Cryptococcus Treatment of patients withspecies,species and/orspecies infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphoteri

Labeler: Eugia US LLCUpdated: 2025-06-12T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Amphotericin B liposome for injection is contraindicated in those patients who have demonstrated or have a known hypersensitivity to amphotericin B deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

14 trials linked to this intervention

14
Total Trials
1
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy of liposomal amphotericin B for treating post-kala-azar dermal leishmaniasis (PKDL): A systematic review and single-arm meta-analysis.
Cavalcante Deivyd Vieira Silva, de Oliveira Lilia Maria Lima, Husain Noor et al. · Diagn Microbiol Infect Dis · 2026
PMID: 41161227Meta-Analysis
Liposomal amphotericin B prophylaxis in paediatrics: a systematic review.
Thorley Emma V, Hatch Jennifer, Li Monica et al. · J Antimicrob Chemother · 2025
PMID: 40493030Meta-AnalysisFull text (PMC)
Transcutaneous Retrobulbar Amphotericin B Injection for Invasive Fungal Sinusitis with Orbital Involvement: A Systematic Review.
Abdulbaki Hasan, Callander Jacquelyn K, Fastenberg Judd H et al. · Am J Rhinol Allergy · 2024
PMID: 38772559Meta-Analysis
Therapeutic drug monitoring of liposomal amphotericin B in children. Are we there yet? A systematic review.
Lai Tony, Yeo Chin-Yen, Rockliff Bradley et al. · J Antimicrob Chemother · 2024
PMID: 38252921Meta-AnalysisFull text (PMC)
Local amphotericin B therapy for Cutaneous Leishmaniasis: A systematic review.
Alves Líndicy Leidicy, Freire Mariana Lourenço, Troian Isadora Lana et al. · PLoS Negl Trop Dis · 2024
PMID: 38626196Meta-AnalysisFull text (PMC)
Advances in nanotechnology for improving the targeted delivery and activity of amphotericin B (2011-2023): a systematic review.
Zadeh Mehrizi Tahereh, Mosaffa Nariman, Vodjgani Mohammad et al. · Nanotoxicology · 2024
PMID: 38646931Meta-Analysis
Safety and Effectiveness of High-dose Liposomal Amphotericin B: A Systematic Review and Meta-analysis.
Fu Xinyin, Zhang Chunping, Lin Xiaoru et al. · Altern Ther Health Med · 2024
PMID: 37971463Meta-Analysis
Nebulized amphotericin B for preventing exacerbations in allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis.
Muthu Valliappan, Dhooria Sahajal, Sehgal Inderpaul Singh et al. · Pulm Pharmacol Ther · 2023
PMID: 37230237Meta-Analysis
Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis.
Stott Katharine E, Moyo Melanie, Ahmadu Ajisa et al. · J Antimicrob Chemother · 2022
PMID: 36411251Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Amphotericin B (substance)
SNOMED CT
77703004
UMLS CUI
C0002679
RxNorm CUI
732
Labeler
Eugia US LLC

Clinical Data

This intervention maps to 17 entities in the Healos knowledge graph.

17
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
14
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.